Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients

Launched by GENESIS ATHENS CLINIC · Jul 22, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called autologous PRP infusion, which involves using a patient’s own platelet-rich plasma (PRP) to see if it can help restore ovarian function in women with premature ovarian insufficiency (POI). POI is a condition where the ovaries stop functioning properly before the age of 40, leading to issues like missed periods and hormonal imbalances. The researchers hope that this treatment might not only help the ovaries work better but also encourage the growth of healthy eggs.

To participate in the study, women who are under 40 years old and have missed their periods for at least four months, along with certain hormone levels that indicate ovarian issues, may be eligible. Participants will need to stop any other treatments related to their condition for a few months before joining the trial. Those who qualify will receive the PRP treatment and could play a role in helping researchers understand how effective this therapy might be for improving ovarian function. If you or someone you know is dealing with POI, this trial could be an opportunity to explore a potential new treatment option.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age \< 40 years, presenting with amenorrhea or menstrual cycle irregularities for at least four months, and elevated FSH levels \>25 IU/L recorded on two occasions \>4 weeks apart
• • Normal Karyotype: 46, XX
• • Discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.
• • Willing to comply with study requirements
• Exclusion Criteria:
• • Any pathological disorder related to reproductive system anatomy
• • AMH \> 8 pmol/L
• • Endometriosis
• • Adenomyosis
• • Fibroids and adhesions
• • Infections in reproductive system
• • Current or previous diagnosis of cancer in reproductive system
• • History of familiar cancer in reproductive system
• • Severe male factor infertility
• • Prior referral for PGT
• • Ovarian inaccessibility
• • Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)
• • BMI\>30 kg/m2 or BMI\<18.5 kg/m2
• • Systematic autoimmune disorders